CD70 binding molecules and methods of use thereof
US11046775B2 · kind B2 · utility
0Cited by
4References
50Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 14, 2018 |
| Grant date | Jun 29, 2021 |
| Priority date | — |
| Expiry date | Apr 25, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides anti-CD70 antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising an antigen binding molecule that specifically binds to CD70, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered TCR and/or CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.